Ferric Contrast, Inc.

📍 Amherst, United States👥 3 employees💰 Last funded 2022
Biotechnology Research🌐 Ferric-Contrast.com
Website LinkedIn
Magnetic Resonance Imaging contrast agents are a lifesaving tool used everyday in all MRI scanners. Poor stability of gadolinium contrast agents has caused changes to the way they are used and regulated. The European Medicines Agency has withdrawn marketing authorization for three widely used contrast agents. Shortly after the EMA’s actions, the FDA issued a class warning on top of an existing Black Box warning. Physicians worldwide have shifted to perceived safer, but more expensive contrast agents. To date there has not been a replacement brought to market. Ferric Contrast, Inc. has developed SafeIron, the successor to gadolinium-based MRI contrast agents. Our iron-based MRI contrast agent produces images equal to the gadolinium-based contrast agents used today and removes their inherent toxicity risks. SafeIron is a drop-in replacement working in all MRI scanners and requiring no workflow changes. SafeIron’s functional component can be mined and refined domestically using a significantly cleaner processes than those for the rare earth element gadolinium. SafeIron’s approval will prevent 20,000kgs of gadolinium being released into drinking water sources yearly.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Ferric Contrast, Inc.?
Ferric Contrast, Inc. has 1 investors on record on gritt.io.
When did Ferric Contrast, Inc. last raise funding?
The most recent investment in Ferric Contrast, Inc. recorded on gritt.io was in 2022.
What industry is Ferric Contrast, Inc. in?
Ferric Contrast, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Ferric Contrast, Inc. based?
Ferric Contrast, Inc. is headquartered in Amherst, United States.